April 2025 in “Journal of Cosmetic Dermatology” Azathioprine is a safe and effective long-term treatment for severe alopecia areata, significantly improving hair regrowth.
June 1982 in “Revista Colombiana de Obstetricia y Ginecología” El acetato de ciproterona trata problemas androgénicos como hirsutismo, acné, seborrea y alopecia con diferentes dosis y combinaciones.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
20 citations
,
August 2021 in “Clinical and Experimental Dermatology” A skin rash after the AstraZeneca COVID-19 vaccine was treated successfully with medication.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
37 citations
,
December 2020 in “Molecules” A new delivery system makes Curcumin more effective and safer against viruses.
6 citations
,
April 2018 in “Transplantation proceedings” A woman experienced severe side effects from a drug due to a specific genetic variation, suggesting genetic testing could prevent such risks.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
December 2025 in “Indian Journal of Case Reports” Stopping azathioprine improved hair loss and bone marrow issues.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
4 citations
,
October 1993 in “Journal of the American Academy of Dermatology” Azelaic acid's effectiveness in treating certain skin conditions needs more research.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
1 citations
,
May 2023 in “Elsevier eBooks”
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
3 citations
,
February 2010 in “Clinical kidney journal” Combining ciclosporin and simvastatin can cause severe kidney damage.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
December 2023 in “International Journal of Dermatology” 71 citations
,
February 2012 in “The American Journal of Human Genetics” A specific ATR gene mutation is linked to a hereditary oropharyngeal cancer syndrome.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
1 citations
,
September 2023 in “Journal of Education Health and Sport” Anabolic-androgenic steroids are dangerous and educating people about their risks is essential.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.